AroCell AB (publ) (AROC.ST)
SEK 0.38
(-4.98%)
SEK 0.38
(-4.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -50.72 Million SEK | 22.19% |
| 2022 | -65.18 Million SEK | -254.25% |
| 2021 | -18.4 Million SEK | 56.2% |
| 2020 | -42.01 Million SEK | -208.21% |
| 2019 | -13.63 Million SEK | 54.16% |
| 2018 | -29.73 Million SEK | -72.38% |
| 2017 | -17.24 Million SEK | 47.49% |
| 2016 | -32.85 Million SEK | 33.37% |
| 2015 | -49.3 Million SEK | -168.48% |
| 2014 | -18.36 Million SEK | -295.3% |
| 2013 | -4.64 Million SEK | -27.95% |
| 2012 | -3.63 Million SEK | -236.67% |
| 2011 | -1.07 Million SEK | -364.26% |
| 2010 | 408.07 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -46.34 Million SEK | 8.63% |
| 2024 Q2 | -48.7 Million SEK | -5.09% |
| 2024 Q3 | -44.53 Million SEK | 8.56% |
| 2023 Q4 | -50.72 Million SEK | 1.53% |
| 2023 FY | -50.72 Million SEK | 22.19% |
| 2023 Q3 | -51.51 Million SEK | 10.49% |
| 2023 Q2 | -57.54 Million SEK | 4.02% |
| 2023 Q1 | -59.95 Million SEK | 8.03% |
| 2022 Q4 | -65.18 Million SEK | 3.89% |
| 2022 FY | -65.18 Million SEK | -254.25% |
| 2022 Q3 | -67.82 Million SEK | 2.85% |
| 2022 Q2 | -69.81 Million SEK | 23.17% |
| 2022 Q1 | -90.87 Million SEK | -393.81% |
| 2021 Q1 | -35.77 Million SEK | 14.84% |
| 2021 Q4 | -18.4 Million SEK | 33.87% |
| 2021 Q2 | -29.69 Million SEK | 16.99% |
| 2021 Q3 | -27.82 Million SEK | 6.31% |
| 2021 FY | -18.4 Million SEK | 56.2% |
| 2020 Q2 | -51.42 Million SEK | 7.91% |
| 2020 Q1 | -55.84 Million SEK | -309.69% |
| 2020 FY | -42.01 Million SEK | -208.21% |
| 2020 Q3 | -45.84 Million SEK | 10.85% |
| 2020 Q4 | -42.01 Million SEK | 8.36% |
| 2019 Q3 | -18.62 Million SEK | 13.09% |
| 2019 Q4 | -13.63 Million SEK | 26.83% |
| 2019 Q2 | -21.43 Million SEK | 15.38% |
| 2019 Q1 | -25.33 Million SEK | 14.81% |
| 2019 FY | -13.63 Million SEK | 54.16% |
| 2018 Q2 | -39.2 Million SEK | -177.34% |
| 2018 FY | -29.73 Million SEK | -72.38% |
| 2018 Q4 | -29.73 Million SEK | 14.03% |
| 2018 Q3 | -34.58 Million SEK | 11.78% |
| 2018 Q1 | -14.13 Million SEK | 18.04% |
| 2017 Q4 | -17.24 Million SEK | 14.59% |
| 2017 FY | -17.24 Million SEK | 47.49% |
| 2017 Q1 | -27.95 Million SEK | 14.91% |
| 2017 Q2 | -24.42 Million SEK | 12.63% |
| 2017 Q3 | -20.19 Million SEK | 17.31% |
| 2016 FY | -32.85 Million SEK | 33.37% |
| 2016 Q1 | -45.21 Million SEK | 8.3% |
| 2016 Q4 | -32.85 Million SEK | 15.81% |
| 2016 Q3 | -39.02 Million SEK | 7.49% |
| 2016 Q2 | -42.18 Million SEK | 6.7% |
| 2015 Q3 | -10.33 Million SEK | 17.84% |
| 2015 FY | -49.3 Million SEK | -168.48% |
| 2015 Q4 | -49.3 Million SEK | -377.23% |
| 2015 Q1 | -14.96 Million SEK | 18.5% |
| 2015 Q2 | -12.57 Million SEK | 15.98% |
| 2014 Q4 | -18.36 Million SEK | -343.14% |
| 2014 Q3 | -4.14 Million SEK | 40.25% |
| 2014 FY | -18.36 Million SEK | -295.3% |
| 2014 Q2 | -6.93 Million SEK | 31.01% |
| 2014 Q1 | -10.05 Million SEK | -116.38% |
| 2013 Q3 | -5.01 Million SEK | 33.16% |
| 2013 Q4 | -4.64 Million SEK | 7.28% |
| 2013 FY | -4.64 Million SEK | -27.95% |
| 2013 Q1 | -2.41 Million SEK | 33.4% |
| 2013 Q2 | -7.49 Million SEK | -209.97% |
| 2012 Q4 | -3.63 Million SEK | -67.23% |
| 2012 Q3 | -2.17 Million SEK | 24.8% |
| 2012 Q1 | -23 Thousand SEK | 97.87% |
| 2012 FY | -3.63 Million SEK | -236.67% |
| 2012 Q2 | -2.88 Million SEK | -12452.17% |
| 2011 FY | -1.07 Million SEK | -364.26% |
| 2011 Q4 | -1.07 Million SEK | 70.82% |
| 2011 Q3 | -3.69 Million SEK | 33.05% |
| 2011 Q2 | -5.51 Million SEK | 0.0% |
| 2010 Q4 | 408.07 Thousand SEK | 0.0% |
| 2010 FY | 408.07 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | -188.09 Million SEK | 73.034% |
| Immunovia AB (publ) | -72.5 Million SEK | 30.039% |
| Prostatype Genomics AB (publ) | -2.61 Million SEK | -1839.694% |
| SenzaGen AB | -15.95 Million SEK | -217.993% |
| Spermosens AB | 5.02 Million SEK | 1109.413% |